1. Home
  2. AVNW vs BMEA Comparison

AVNW vs BMEA Comparison

Compare AVNW & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVNW
  • BMEA
  • Stock Information
  • Founded
  • AVNW 2006
  • BMEA 2017
  • Country
  • AVNW United States
  • BMEA United States
  • Employees
  • AVNW N/A
  • BMEA N/A
  • Industry
  • AVNW Radio And Television Broadcasting And Communications Equipment
  • BMEA Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVNW Technology
  • BMEA Health Care
  • Exchange
  • AVNW Nasdaq
  • BMEA Nasdaq
  • Market Cap
  • AVNW 291.3M
  • BMEA 65.8M
  • IPO Year
  • AVNW 2007
  • BMEA 2021
  • Fundamental
  • Price
  • AVNW $24.06
  • BMEA $1.85
  • Analyst Decision
  • AVNW Strong Buy
  • BMEA Strong Buy
  • Analyst Count
  • AVNW 5
  • BMEA 10
  • Target Price
  • AVNW $37.60
  • BMEA $22.30
  • AVG Volume (30 Days)
  • AVNW 94.1K
  • BMEA 5.6M
  • Earning Date
  • AVNW 05-06-2025
  • BMEA 07-30-2025
  • Dividend Yield
  • AVNW N/A
  • BMEA N/A
  • EPS Growth
  • AVNW N/A
  • BMEA N/A
  • EPS
  • AVNW N/A
  • BMEA N/A
  • Revenue
  • AVNW $435,926,000.00
  • BMEA N/A
  • Revenue This Year
  • AVNW $8.46
  • BMEA N/A
  • Revenue Next Year
  • AVNW $5.21
  • BMEA N/A
  • P/E Ratio
  • AVNW N/A
  • BMEA N/A
  • Revenue Growth
  • AVNW 14.58
  • BMEA N/A
  • 52 Week Low
  • AVNW $12.96
  • BMEA $1.29
  • 52 Week High
  • AVNW $31.74
  • BMEA $13.07
  • Technical
  • Relative Strength Index (RSI)
  • AVNW 69.77
  • BMEA 45.95
  • Support Level
  • AVNW $22.16
  • BMEA $1.81
  • Resistance Level
  • AVNW $22.94
  • BMEA $3.08
  • Average True Range (ATR)
  • AVNW 0.73
  • BMEA 0.24
  • MACD
  • AVNW 0.06
  • BMEA -0.07
  • Stochastic Oscillator
  • AVNW 94.72
  • BMEA 15.13

About AVNW Aviat Networks Inc.

Aviat Networks Inc is a networking solutions provider. It designs, manufactures and sells wireless networking products, solutions, and services to mobile and fixed operators, private network operators, government agencies, transportation and utility companies, public safety agencies, and broadcast network operators around the world. The company's product categories include point-to-point microwave and millimeter wave radios that are licensed (subject to local frequency regulatory requirements), lightly licensed and license-exempt (operating in license-exempt frequencies), and element and network management software.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: